Verily drew widespread praise last year when it announced an “ambitious endeavor” to combat the opioid epidemic: an addiction medicine campus in Ohio called OneFifteen, its name a nod to the 115 people who died each day in 2017 of opioid overdoses.
But in the year and a half since OneFifteen’s high-profile launch, Verily has remained relatively quiet about its progress — and its role in the effort, which is a collaboration between the Alphabet life science subsidiary and two local health systems.
About the Author Reprints
